Michail Ignatiadis, MD PhD is senior attending physician at the Medical Oncology Department, Jules Bordet Institute (IJB) and associate professor at the Université Libre de Bruxelles, Belgium. Since January 2021, he is the chair of the breast cancer group of the EORTC. He is also leading the Academic Trials Promoting Team (ATPT) and he is member of the Executive and Research Boards of IJB since October 2016. He participates in developing the IJB research strategy. He works with his team and members of the Executive and Research Boards to promote high-quality, innovative, academic research at the institutional level.

From June 2018 to January 2021, he served in the Board of Directors of the EORTC as the chair of the clinical research division. He has been involved in many investigator-initiated trials (IITs) sponsored by IJB at different stages of their development. He has been member of the Independent Data Monitoring Committees for international trials and study chair of several IITs. He served as IJB principal investigator for many industry sponsored trials. Currently, he is the study chair of the Alexandra/Impassion030 registration trial.

He is particularly interested in drug and biomarker development in breast cancer. His work in the field of blood-based biomarkers is widely recognised at the international level.

He has published more than 100 articles in peer reviewed journals including several papers in high impact factor journals such as Journal of Clinical Oncology, Nature Reviews Clinical Oncology, JAMA Oncology, Journal of National Cancer Institute, Lancet Oncology as well as several book chapters; he is editor of a book on minimal residual disease.

He has served as reviewer for several national and international organisations including the French National Cancer Institute (INCA), the Technology Foundation STW in the Netherlands, the Marie-Curie Fellowships, the European Research Council (ERC) and the Innovative Medicines Initiative (IMI).

He has served as Chair or Co-Chair of symposia in high visibility international conferences, organised by ESMO, ECCO and ASCO. He has served as faculty in the prestigious workshop ‘Methods in Clinical Cancer Research’ every year from 2014 until 2019.

He has obtained independent research funding over the last 6 years.